Plasma Fractionation Market Competitive Landscape and Emerging Trends in Therapeutic Use of Albumin and Coagulation Factors

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Plasma Fractionation Market- (By Product (Immune-Globulins(Intravenous Immune-Globulins, Subcutaneous Immune-Globulins, Other Immune-Globulins), Coagulation Factor Concentrates (Factor VIII, Factor IX, Von Willebrand Factor, Prothrombin Complex Concentrate, Fibrinogen Concentrates, Factor XIII, Others), Albumin, Protease Inhibitors, Other Plasma Products), By Application (Neurology, Immunology, Hematology, Critical Care, Pulmonology, Hemato-Oncology, Rheumatology, Others), By End-User (Hospitals & Clinics, Clinical Research Laboratories, Academic Institutes)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global Plasma Fractionation Market is valued at USD 4.2 Bn in 2023, and it is expected to reach USD 8.9 Bn by the year 2031with a CAGR of 10.1% during a forecast period of 2023-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2140

Fractionation refers to the process of separating specific components from a mixture. In the context of healthcare, plasma-the liquid component of blood-is fractionated to obtain various therapeutic derivatives, including albumin and immunoglobulins. These plasma-derived products are essential in the treatment of a wide range of plasma-related disorders. A key factor propelling the growth of the plasma fractionation market is the increasing global geriatric population, which is more susceptible to rare diseases requiring plasma-based therapies.

Additionally, the rising demand for immunoglobulins and alpha-1 antitrypsin across various medical applications is significantly contributing to market expansion. The global increase in plasma collection centers is another important factor supporting growth. Furthermore, favorable government initiatives aimed at raising awareness about the benefits and applications of plasma-derived therapies are expected to further accelerate the development of the plasma fractionation market.

Prominent Players in the Plasma Fractionation Market:
• CSL (Australia)
• Takeda Pharmaceutical Company Limited (Japan)
• Grifols, S.A. (Spain)
• Octapharma AG (Switzerland)
• Kedrion S.P.A (Italy)
• LFB (France)
• ADMA Biologics (US)
• Sanquin (Netherlands)
• China Biologic Products Holdings Inc. (China)
• GC Pharma (Korea)
• Hualan Bioengineering Co., Ltd. (China)
• Japan Blood Products Organization (Japan)
• Emergent BioSolutions (US)
• Shanghai Raas Blood Products Co., Ltd. (China)
• Intas Pharmaceuticals Ltd. (India)
• Bharat Serum Vaccines Limited (India)
• SK Plasma (Korea)
• Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China)
• Kamada (Israel)
• Centurion Pharma (Istanbul)
• Prothya Biosolutions (Netherlands)
• PlasmaGen BioSciences Pvt. Ltd. (India)
• Virchow Biotech Private Limited (India)
• Fusion Healthcare (India)
• Hemarus Therapeutics Limited (India)
• Others

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-01

Market Dynamics
Drivers:
The increasing prevalence of immunodeficiency disorders is a key factor propelling the growth of the plasma fractionation market. Globally, there has been a significant surge in the demand for plasma-derived therapies, particularly immunoglobulins, which has positively influenced overall market expansion. In response to this growing demand, leading market players have intensified their research and development efforts to introduce innovative plasma-based therapeutics. Additionally, these companies are actively investing in and acquiring plasma collection centers to enhance the supply chain and ensure consistent availability of plasma for the development of new treatments. The rise in immunodeficiency cases worldwide continues to be a primary driver supporting the demand for plasma-derived products.

Challenges:
The growing adoption of recombinant therapies presents a considerable challenge to the expansion of the plasma fractionation market. Recombinant alternatives to plasma-derived medications have gained traction due to their lower immunogenicity and suitability for prophylactic use. These products offer key benefits, including extended half-life, reduced frequency of administration, and improved efficacy in preventive treatments. The increasing preference for recombinant components in clinical settings is thereby limiting the uptake of traditional plasma-based therapies.

Regional Trends:
The Asia-Pacific region is anticipated to command a significant share of the plasma fractionation market and is projected to grow at a robust compound annual growth rate (CAGR) in the coming years. This growth is supported by the presence of major companies engaged in the development and commercialization of advanced plasma-derived products. In parallel, North America is expected to experience strong market growth, driven largely by the United States, which hosts the highest number of plasma fractionation centers globally. This well-established infrastructure substantially contributes to the region's market expansion.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2140

Recent Developments:
• In March 2023, Takeda made an investment of 100 billion JPY in the establishment of a novel manufacturing facility in Japan, specifically dedicated to the production of plasma-derived medicines. The investment made by Takeda exemplified the company's dedication to prioritising patients and fulfilling its obligations in relation to its patient-centric, people-oriented, and environmentally conscious objectives. This approach was supported by the utilisation of data and digital technologies.
• In Dec 2022, CSL has recently inaugurated its Plasma Fractionation Facility in Victoria, Australia, which represents a significant milestone in the country's plasma manufacturing sector. With a staggering investment of $900 Bn, this state-of-the-art facility stands as the largest of its type in the Southern Hemisphere. The aforementioned statement pertains to a capital investment programme of over $2 billion that CSL is presently implementing in Australia.

Segmentation of Plasma Fractionation Market-
By Product-
• Immune-Globulins
o Intravenous Immune-Globulins
o Subcutaneous Immune-Globulins
o Other Immune-Globulins
• Coagulation Factor Concentrates
o Factor VIII
o Factor IX
o Von Willebrand Factor
o Prothrombin Complex Concentrate
o Fibrinogen Concentrates
o Factor XIII
o Others
• Albumin
• Protease Inhibitors
• Other Plasma Products
By Application-
• Neurology
• Immunology
• Hematology
• Critical Care
• Pulmonology
• Hemato-Oncology
• Rheumatology
• Others
By End-User-
• Hospitals & Clinics
• Clinical Research Laboratories
• Academic Institutes
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/plasma-fractionation-market/2140

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.